🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being viewed as a "major milestone" in the battle against increasingly resistant strains of the bacteria, according to researchers.

A Worldwide Public Health Issue

The sexually transmitted infection are increasing globally, with data suggesting over 82 million new cases each year. Especially elevated rates are observed in Africa and nations within the WHO's designated area, which spans from Mongolia and China to New Zealand. Across England, cases have reached a record high, while rates across Europe in 2023 were three times higher compared to the rates from 2014.

“The authorization of new treatments for gonorrhoea is an significant and necessary advancement in the context of increasing worldwide cases, the spread of superbugs and the highly restricted treatment choices at this time.”

Health officials are increasingly worried about the increase in treatment-resistant strains. The WHO has classified it as a "high-priority threat". Recent surveillance showed that the effectiveness of key first-line drugs like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

A Pair of Novel Drugs Secure Clearance

One new antibiotic, also known as a brand name, was authorized by the American regulatory agency in recent days for combating gonorrhoea. This STI can lead to major issues, including the inability to conceive. Researchers anticipate that specific application of this new drug will help delay the spread of drug resistance.

Another new antibiotic, developed by the drugmaker GSK, gained clearance in close succession. This treatment, which is also used to treat urinary tract infections, was proven in research to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

A Unique Development Model

This new treatment stemmed from a new, not-for-profit approach for antibiotic development. The charitable organization GARDP worked alongside the drug firm Innoviva to bring it to fruition.

“This approval signifies a significant shift in the management of highly resistant gonorrhoea, which up to this point has been evolving faster than our drug pipeline.”

Testing Data and Worldwide Availability

Based on results published in a major medical journal, zoliflodacin eradicated the vast majority of genital gonorrhoea infections. This places it at an comparable level with the current standard treatment, which combines an injection and a pill. The trial involved nearly 1,000 patients from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its development partnership, GARDP has the ability to make available and distribute the drug in many developing nations.

Doctors directly involved have expressed optimism. The availability of a one-pill regimen of this kind is described as a "revolutionary step" for gonorrhoea control. This is deemed crucial to alleviate the strain of the illness for people and to stop the proliferation of untreatable gonorrhoea around the world.